GENFIT's GNS561 Combination Therapy Shows Tumor Control Potential
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 23 hour ago0mins
- Clinical Trial Progress: The ongoing Phase 1b study shows that the combination of GNS561 and MEK inhibitors achieves disease stabilization in all evaluable patients, with tumor shrinkage observed in a subset, indicating potential efficacy in difficult-to-treat cholangiocarcinoma.
- Patient Recruitment Status: No dose-limiting toxicities have been reported to date, enabling the recruitment of a third patient cohort, with recommended Phase 2 doses expected in 1H26, reflecting a positive outlook for the study.
- Addressing Treatment Needs: The combination therapy has achieved disease control in patients who have failed multiple prior treatments, fulfilling a critical unmet medical need and potentially offering new hope for these patients.
- Future Development Plans: The Phase 1b dose escalation will continue as planned, with new data expected in Q1 2026 to support the initiation of Phase 2, further validating the clinical benefits of this combination approach.
GNFT.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on GNFT
Wall Street analysts forecast GNFT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNFT is 7.50 USD with a low forecast of 7.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.850
Low
7.00
Averages
7.50
High
8.00
Current: 4.850
Low
7.00
Averages
7.50
High
8.00
H.C. Wainwright
Buy
downgrade
$9 -> $7
2025-09-24
Reason
H.C. Wainwright
Price Target
$9 -> $7
2025-09-24
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Genfit to $7 from $9 and keeps a Buy rating on the shares. The company last week announced the discontinuation of VS-01 in acute on chronic liver failure following a case of peritonitis in the UNVEIL-IT study, the analyst tells investors in a research note. The firm updated Genfit's model for the discontinuation and the company's half year earnings report.
H.C. Wainwright
H.C. Wainwright
initiated
$9
2025-08-19
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$9
2025-08-19
initiated
Reason
H.C. Wainwright assumed coverage of Genfit with a Buy rating and $9 price target. The company is developing therapies for rare and severe liver diseases, with a focus on acute-on-chronic liver failure, the analyst tells investors in a research note. The firm says the company is expected to readout multiple meaningful clinical updates in 2025 and beyond, providing a number of catalysts for the shares.
HC Wainwright & Co.
Ed Arce
Strong Buy
Reiterates
$13
2025-02-07
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$13
2025-02-07
Reiterates
Strong Buy
Reason
See All Ratings
About GNFT
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What is the significance of GNS561 in combination with MEK inhibitors?
How does the combination therapy address unmet medical needs in cholangiocarcinoma?
What are the chances of Phase 2 trials starting as planned in 2026?
How likely is the combination therapy to gain regulatory approval in the future?